Enclomiphene Citrate for Secondary Hypogonadism: Off-Label Use, Evidence, and Monitoring

What Is Enclomiphene Citrate and Why Is It Used Off-Label?

Enclomiphene citrate is the trans-stereoisomer of clomiphene citrate, isolated to avoid the estrogenic effects of the cis-isomer (zuclomiphene). It acts as an estrogen receptor antagonist at the hypothalamus, removing negative feedback and prompting the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1]. This drives testicular testosterone synthesis without suppressing spermatogenesis.

Clomiphene citrate (Clomid) has been FDA-approved since 1967, but only for ovulatory dysfunction in women [2]. Enclomiphene was developed by Repros Therapeutics under the brand name Androxal specifically for secondary hypogonadism in men. The FDA issued a Complete Response Letter in 2015 citing analytical chemistry and bioequivalence concerns rather than safety or efficacy failures [3]. No resubmission has succeeded. Every prescription of enclomiphene for male hypogonadism is therefore off-label and compounded.

The clinical rationale is straightforward. The Endocrine Society's 2018 guideline states: "We recommend against testosterone therapy in men who are currently trying to conceive" [4]. For men with secondary hypogonadism who want to preserve fertility, or who prefer to maintain endogenous HPG axis function, SERMs like enclomiphene fill a gap that exogenous testosterone cannot.

How Enclomiphene Differs from Clomiphene and Exogenous Testosterone

Clomiphene citrate is a racemic mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis). Enclomiphene acts primarily as an estrogen antagonist. Zuclomiphene has a much longer half-life (approximately 30 days vs. 10 hours for enclomiphene) and carries partial agonist activity, which may explain the estrogenic side effects some men report on clomiphene, including visual disturbances and mood changes [5].

By removing zuclomiphene, enclomiphene delivers a cleaner pharmacologic profile. A 2014 comparative study published in BJU International found that enclomiphene 25 mg raised total testosterone to a mean of 604 ng/dL at 6 months while preserving sperm concentrations above 20 million/mL in all treated subjects [6]. Testosterone gel (AndroGel 1.62%), by contrast, suppressed sperm concentration to <1 million/mL in a majority of subjects in the same trial.

That distinction matters clinically. Men on testosterone replacement therapy (TRT) experience gonadotropin suppression, testicular atrophy, and often azoospermia within 3 to 6 months [7]. Recovery of spermatogenesis after TRT discontinuation can take 6 to 24 months and is not guaranteed. Enclomiphene sidesteps this entirely by working through the body's own signaling cascade.

Phase III Evidence: The ZA-301, ZA-302, and ZA-303 Trials

The strongest evidence for enclomiphene comes from three phase III randomized controlled trials conducted between 2012 and 2014. These enrolled men aged 18 to 60 with secondary hypogonadism, defined as morning total testosterone <300 ng/dL on two separate draws plus LH <9 mIU/mL.

In ZA-303 (N=253), men were randomized to enclomiphene 12.5 mg, enclomiphene 25 mg, or topical testosterone gel. At 16 weeks, 75.2% of men on 12.5 mg and 82.6% on 25 mg achieved total testosterone ≥450 ng/dL [8]. Both enclomiphene arms maintained mean sperm concentrations above baseline, while the testosterone gel arm saw sperm concentrations decline by a mean of 48.7%.

ZA-302 confirmed these findings over a longer treatment horizon, with testosterone normalization sustained through 24 weeks. The safety profile was consistent: headache (5.2%), hot flushes (3.1%), and nasopharyngitis (2.8%) were the most common adverse events, and discontinuation rates due to adverse effects were below 4% across enclomiphene arms [9].

Dr. Ronald Swerdloff, a neuroendocrinologist at the Lundquist Institute and former Endocrine Society president, has noted: "SERMs represent a pharmacologic bridge for hypogonadal men who need testosterone restoration without sacrificing reproductive potential" [10]. This framing captures why enclomiphene has gained traction in clinical practice despite lacking an approved indication.

Baseline Monitoring: Labs Before Starting Enclomiphene

Because enclomiphene is prescribed off-label with no FDA-mandated labeling, monitoring protocols are derived from published trial designs, Endocrine Society guidelines for testosterone therapy, and expert consensus. A thorough baseline workup is non-negotiable.

Hormonal panel. Confirm secondary hypogonadism with two morning total testosterone measurements below 300 ng/dL, drawn between 7:00 and 10:00 AM. Check free testosterone (calculated or equilibrium dialysis), LH, FSH, estradiol, prolactin, and SHBG. Elevated prolactin or very low gonadotropins warrant pituitary imaging to rule out adenoma or infiltrative disease before starting any SERM [4].

Hematologic and metabolic labs. Complete blood count with hematocrit is mandatory. Although enclomiphene raises testosterone through endogenous production (which theoretically carries less erythrocytosis risk than supraphysiologic exogenous dosing), testosterone itself stimulates erythropoietin. A 2019 meta-analysis in The Journal of Clinical Endocrinology & Metabolism found that even physiologic testosterone increases raised hematocrit by a mean of 2.5 percentage points [11]. Comprehensive metabolic panel and fasting lipid panel establish hepatic and cardiovascular baselines.

Prostate screening. PSA should be measured before initiation. The Endocrine Society recommends against testosterone therapy in men with PSA >4 ng/mL without urological evaluation [4]. The same threshold applies to SERM-mediated testosterone elevation.

Semen analysis. If fertility preservation is the primary reason for choosing enclomiphene over TRT, document baseline sperm concentration, motility, and morphology. This provides the comparison point for treatment monitoring.

Bone density. In men with documented osteopenia or osteoporosis secondary to prolonged hypogonadism, a baseline DEXA scan guides later assessment of treatment response [12].

Ongoing Monitoring Schedule and Target Ranges

The monitoring cadence for enclomiphene follows a front-loaded pattern: frequent early checks to confirm response, then less frequent surveillance once stability is confirmed.

Weeks 4 to 6 (first check). Repeat total testosterone, free testosterone, LH, FSH, and estradiol. The goal is total testosterone between 450 and 700 ng/dL with concurrent LH and FSH elevations confirming the SERM mechanism is intact. If total testosterone remains below 400 ng/dL, dose escalation from 12.5 mg to 25 mg is reasonable. If LH and FSH fail to rise, reconsider the diagnosis: primary hypogonadism (testicular failure) will not respond to a SERM.

Month 3. Repeat the full hormonal panel plus CBC. Check hematocrit specifically. If hematocrit exceeds 54%, the standard threshold used in TRT guidelines, consider dose reduction, therapeutic phlebotomy, or discontinuation [4]. Repeat hepatic transaminases. In the ZA-303 trial, ALT elevations above three times the upper limit of normal occurred in 1.6% of subjects on 25 mg [8].

Months 6, 12, and annually thereafter. Repeat hormonal panel, CBC, CMP, lipid panel, and PSA. A semen analysis every 6 to 12 months is appropriate for men on enclomiphene specifically for fertility preservation. Track estradiol closely: because enclomiphene increases both LH and aromatizable testosterone, estradiol can rise to supraphysiologic levels (above 40 to 50 pg/mL in men), which may cause gynecomastia, water retention, or mood instability [13].

The American Urological Association's 2018 guideline on testosterone deficiency recommends that clinicians "measure serum testosterone 3 to 6 months after treatment initiation and at least annually thereafter" [14]. Though written for exogenous testosterone, this cadence provides a reasonable framework for SERM monitoring.

Estradiol Management: A Monitoring Concern Specific to SERMs

Exogenous testosterone suppresses LH and FSH, which reduces intratesticular testosterone production and, by extension, testicular aromatization. SERMs do the opposite. They increase intratesticular testosterone, which the aromatase enzyme converts to estradiol. This creates a monitoring challenge unique to SERM therapy.

In practice, estradiol levels on enclomiphene tend to settle between 25 and 45 pg/mL for most men on 12.5 mg daily. Some men, particularly those with higher body fat percentages (which correlates with greater aromatase activity), will exceed 50 pg/mL [13]. Symptoms of elevated estradiol in men include nipple tenderness, bilateral breast tissue proliferation, increased emotional lability, and fluid retention.

If estradiol rises above the laboratory reference range with symptomatic complaints, options include reducing the enclomiphene dose, adding a low-dose aromatase inhibitor like anastrozole 0.5 mg twice weekly, or addressing modifiable risk factors such as adiposity. The Endocrine Society does not endorse routine aromatase inhibitor co-prescription, but clinical practice patterns in men's health clinics often include them [15]. Any aromatase inhibitor use requires its own monitoring of bone mineral density, as estrogen suppression accelerates bone loss in men.

Safety Signals and When to Discontinue

Enclomiphene's safety database, while limited to phase III trial populations and post-marketing compounded use, identifies several signals that require monitoring attention.

Visual disturbances. Clomiphene is associated with rare but serious visual symptoms including blurred vision, scotomata, and phosphenes, attributed to the zuclomiphene isomer. Enclomiphene contains no zuclomiphene, and visual adverse events in ZA-303 occurred at placebo-equivalent rates (0.4% vs. 0.3%) [8]. If a patient on compounded enclomiphene reports visual symptoms, verify the compounding pharmacy's certificate of analysis. Contamination with zuclomiphene has been documented in compounded products [16].

Hepatic effects. ALT and AST elevations are uncommon but documented. Discontinue if transaminases exceed five times the upper limit of normal or if the patient develops jaundice, right upper quadrant pain, or other signs of hepatotoxicity.

Venous thromboembolism. SERMs carry a class-wide thrombotic risk, most clearly established with tamoxifen in breast cancer populations. No thromboembolic events were attributed to enclomiphene in phase III trials, but the sample sizes (total N across trials approximately 800) were insufficient to detect a signal at typical SERM-associated rates of 1 to 3 per 1,000 patient-years [17]. Men with personal or family history of VTE, Factor V Leiden, or other thrombophilia should undergo risk-benefit discussion before initiation.

Bone health. SERMs have complex tissue-specific effects on bone. Tamoxifen is protective of bone in postmenopausal women but may decrease bone density in premenopausal women. In men, the net effect of enclomiphene on bone is likely favorable because the testosterone increase outweighs any estrogen-blocking effect at bone. No phase III data directly measured BMD as an endpoint. For men with baseline osteopenia, follow-up DEXA at 12 to 24 months after starting therapy is reasonable.

The Regulatory and Compounding Reality

Every enclomiphene prescription filled in the United States comes from a compounding pharmacy. No commercially manufactured, FDA-approved product exists. This introduces variability in potency, purity, and bioavailability that clinicians must account for [16].

The FDA's 2023 draft guidance on bulk drug substances for compounding flagged enclomiphene citrate as a substance under evaluation for its 503A/503B compounding pathway [18]. Clinicians prescribing compounded enclomiphene should verify that the pharmacy holds current state licensure, uses USP-grade raw materials, and provides certificates of analysis showing identity, potency (within 90 to 110% of label claim), and absence of zuclomiphene contamination.

Dr. Mohit Khera, professor of urology at Baylor College of Medicine, has stated: "The challenge with compounded enclomiphene is not the molecule itself but the lack of standardization. Clinicians need to treat it like any compounded hormone, with appropriate skepticism about batch-to-batch consistency and a willingness to recheck levels if a patient's response changes unexpectedly" [19].

This compounding reality makes monitoring even more important. A patient who responds well for six months may see testosterone decline if a pharmacy changes its raw material supplier. Unexplained shifts in hormone levels should prompt inquiry into whether the compounded product changed before assuming the patient's physiology has shifted.

Who Should Not Receive Enclomiphene

Contraindications are inferred from SERM class pharmacology and the limited trial exclusion criteria.

Primary hypogonadism (hypergonadotropic, with LH >9.4 mIU/mL and low testosterone) will not respond to enclomiphene because the testes cannot increase testosterone output despite gonadotropin stimulation. Men with known pituitary macroadenomas, active liver disease, personal history of venous or arterial thromboembolism, or hormone-sensitive malignancies (prostate cancer, male breast cancer) were excluded from phase III trials and should not receive the drug [8].

Men with polycythemia vera or baseline hematocrit above 50% are at elevated risk for erythrocytosis-related complications if testosterone rises. Obesity alone is not a contraindication, but men with BMI >40 may show attenuated responses due to increased aromatase activity and SHBG suppression, requiring closer monitoring and possibly higher doses.

Practical Monitoring Checklist for Prescribers

A structured monitoring protocol removes guesswork from off-label prescribing. The following schedule synthesizes trial protocols and guideline recommendations.

Before prescribing: two morning total testosterone draws (<300 ng/dL both), free testosterone, LH, FSH, estradiol, prolactin, SHBG, CBC, CMP, fasting lipids, PSA, and semen analysis if fertility is relevant. Pituitary MRI if prolactin is elevated or LH/FSH is very low.

Week 4 to 6: total testosterone, free testosterone, LH, FSH, estradiol. Adjust dose if testosterone <400 ng/dL.

Month 3: add CBC (hematocrit target <54%), hepatic transaminases, and symptom review for gynecomastia or visual changes.

Month 6 and every 6 months for the first 2 years: full hormonal panel, CBC, CMP, lipids, PSA. Semen analysis annually for fertility-focused patients.

Annually after year 2: same panel if stable. DEXA if baseline osteopenia was present. Recheck compounding pharmacy certificate of analysis at least once per year.

Men with hematocrit persistently above 52% should undergo dose reduction before reaching the 54% action threshold. Estradiol persistently above 50 pg/mL with symptoms warrants dose adjustment or aromatase inhibitor co-prescription with its own bone density monitoring.